Mn(II)-based sensors to detect zinc in vivo with MRI
In some aspects, the present disclosure provides compounds of the formula: wherein the variables are defined herein. In some aspects, the present disclosure provides methods of preparing imaging agents, compositions thereof, and methods of imaging using said imaging agents or compositions thereof.
1. A compound of the formula:
wherein:
n is 1, 2, 3, 4, 5, or 6;
o and p are each independently 1, 2, or 3;
A 1 is heteroarenediyl (C≤12) or substituted heteroarenediyl (C≤12) ;
R 1 and R 2 are each independently hydrogen; or
alkyl (C≤12) , aryl (C≤12) , heteroaryl (C≤12) , or a substituted version of any of these groups; or
R 1 and R 2 are taken together and are alkanediyl (C≤12) , substituted alkanediyl (C≤12) , alkenediyl (C≤12) , or substituted alkenediyl (C≤12) ;
R 3 and R 4 are each independently heteroaryl (C≤12) or substituted heteroaryl (C≤12) ;
Y 1 , Y 2 , Y 3 , and Y 4 are each independently alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; and
Y 5 is a covalent bond or —C(O)—; or
alkanediyl (C≤12) , substituted alkanediyl (C≤12) , -alkanediyl (C≤12) -C(O)—, or substituted -alkanediyl (C≤12) -C(O)—;
or a metal complex, a deprotonated form, a hydrate, or a salt thereof.
2. The compound of claim 1 , further defined as:
wherein:
n is 1, 2, 3, 4, 5, or 6;
o and p are each independently 1, 2, or 3;
R 1 and R 2 are each independently hydrogen; or
alkyl (C≤12) , aryl (C≤12) , heteroaryl (C≤12) , or a substituted version of any of these groups; or
R 1 and R 2 are taken together and are alkanediyl (C≤12) , substituted alkanediyl (C≤12) , alkenediyl (C≤12) , or substituted alkenediyl (C≤12) ;
R 3 and R 4 are each independently heteroaryl (C≤12) or substituted heteroaryl (C≤12) ;
Y 1 , Y 2 , Y 3 , and Y 4 are each independently alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; and
Y 5 is a covalent bond or —C(O)—; or
alkanediyl (C≤12) , substituted alkanediyl (C≤12) , -alkanediyl (C≤12) -C(O)—, or substituted -alkanediyl (C≤12) -C(O)—;
or a metal complex, a deprotonated form, a hydrate, or a salt thereof.
3. The compound of either claim 1 , further defined as:
wherein:
n is 1, 2, 3, 4, 5, or 6;
o and p are each independently 1, 2, or 3;
R 1 and R 2 are each independently hydrogen; or
alkyl (C≤12) , aryl (C≤12) , heteroaryl (C≤12) , or a substituted version of any of these groups; or
R 1 and R 2 are taken together and are alkanediyl (C≤12) , substituted alkanediyl (C≤12) , alkenediyl (C≤12) , or substituted alkenediyl (C≤12) ;
R 3 and R 4 are each independently heteroaryl (C≤12) or substituted heteroaryl (C≤12) ;
Y 1 , Y 2 , Y 3 , and Y 4 are each independently alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; and
Y 5 is a covalent bond or —C(O)—; or
alkanediyl (C≤12) , substituted alkanediyl (C≤12) , -alkanediyl (C≤12) -C(O)—, or substituted -alkanediyl (C≤12) -C(O)—;
or a metal complex, a deprotonated form, a hydrate, or a salt thereof.
4. The compound of according to claim 1 , further defined as:
wherein:
n is 1, 2, 3, 4, 5, or 6;
o and p are each independently 1, 2, or 3;
R 3 and R 4 are each independently heteroaryl (C≤12) or substituted heteroaryl (C≤12) ;
Y 1 , Y 2 , Y 3 , and Y 4 are each independently alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; and
Y 5 is a covalent bond or —C(O)—; or
alkanediyl (C≤12) , substituted alkanediyl (C≤12) , -alkanediyl (C≤12) -C(O)—, or substituted -alkanediyl (C≤12) -C(O)—;
or a metal complex, a deprotonated form, a hydrate, or a salt thereof.
5. The compound of according to claim 1 , further defined as:
wherein:
n is 1, 2, 3, 4, 5, or 6;
o and p are each independently 1, 2, or 3;
R 3 and R 4 are each independently heteroaryl (C≤12) or substituted heteroaryl (C≤12) ;
Y 5 is a covalent bond or —C(O)—; or
alkanediyl (C≤12) , substituted alkanediyl (C≤12) , -alkanediyl (C≤12) -C(O)—, or substituted -alkanediyl (C≤12) -C(O)—;
or a metal complex, a deprotonated form, a hydrate, or a salt thereof.
6. The compound according to claim 1 , wherein R 3 is heteroaryl (C≤12) .
7. The compound according to claim 1 , wherein p is 1 or 2.
8. The compound according to claim 1 , wherein Y 5 is —C(O)—.
9. The compound of claim 1 further defined as:
or a metal complex, a deprotonated form, a hydrate, or a salt thereof.
10. The compound of claim 1 , further defined as a metal complex of the formula:
or a deprotonated form, a hydrate, or a salt thereof.
11. The compound of claim 1 , further defined as a hydrate of the formula:
or a deprotonated form or a salt thereof.
12. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 , wherein the composition is formulated for administration orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularlly, intravitreally, liposomally, locally, mucosally, parenterally, rectally, subconjunctival, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in crémes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, or via localized perfusion.
14. The pharmaceutical composition of claim 13 , wherein the composition is formulated for administration intraprostatically or intravenously.
15. The pharmaceutical composition according to claim 12 , formulated as a unit dose form in an amount sufficient to image a patient when administered thereto.
16. A method of imaging a patient comprising the steps of:
a) administering to the patient a compound or composition of claim 1 ; and
b) obtaining an imaging scan of the patient.
17. A method of imaging the pancreas in vivo in a patient to determine the onset of β-cell degeneration comprising the steps of:
a) administering to the patient a compound or composition of claim 1 ;
b) obtaining an imaging scan of the patient; and
c) determining the presence of Zn 2+ ions.
18. A method of imaging the prostate in vivo in a patient to determine the presence of a prostate tumor comprising the steps of:
a) administering to the patient a compound or composition of claim 1 ;
b) obtaining an imaging scan of the patient; and
c) determining the presence of Zn 2+ ions.